<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mimmun</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинская иммунология</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Immunology (Russia)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1563-0625</issn><issn pub-type="epub">2313-741X</issn><publisher><publisher-name>SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15789/1563-0625-2015-3-221-228</article-id><article-id custom-type="elpub" pub-id-type="custom">mimmun-886</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>КЛИНИЧЕСКАЯ ЗНАЧИМОСТЬ ЭКСПРЕССИИ Toll2, Toll4, CD14, HLA-DR НА МОНОЦИТАХ У ПАЦИЕНТОВ С СЕПСИСОМ</article-title><trans-title-group xml:lang="en"><trans-title>CLINICAL SIGNIFICANCE OF Toll2, Toll4, CD14, AND HLA-DR EXPRESSION ON THE MONOCYTES IN PATIENTS WITH SEPSIS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лазанович</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Lazanovich</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кандидат медицинских наук, ассистент кафедры клинической лабораторной диагностики, общей и клинической иммунологии.</p><p>Адрес для переписки: Лазанович Владимир Анатольевич ГБОУ ВПО «Тихоокеанский государственный медицинский университет» Министерства здравоохранения РФ 690062, Россия, г. Владивосток, пр. 100-я Владивостока, 14-49. Тел.: 8 (914) 703-45-09. E-mail: immuno2003@mail.ru</p></bio><bio xml:lang="en"><p>PhD (Medicine), Assistant Professor, Department of Clinical Laboratory Diagnostics, General and Clinical Immunology.</p><p>Address for correspondence: Lazanovich Vladimir A. G.P. Somov Research Institute of Epidemiology and Microbiology, Siberian Branch of Russian Academy of Medical Sciences 690062,Russian Federation,Vladivostok, The stoletiya pr., 14-49. Phone: 7 (914) 703-45-09. E-mail: immuno2003@mail.ru</p></bio><email xlink:type="simple">immuno2003@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Маркелова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Markelova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Доктор медицинских наук, профессор, заведующая кафедрой физиологии человека</p></bio><bio xml:lang="en"><p>PhD, MD (Medicine), Professor, Head, Department of Human Physiology</p></bio><email xlink:type="simple">immuno2003@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Смирнов</surname><given-names>Г. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Smirnov</surname><given-names>G. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кандидат медицинских наук, доцент кафедры реанимации, анестезиологии, интенсивной терапии и скорой медицинской помощи</p></bio><bio xml:lang="en"><p>PhD (Medicine), Associate Professor, Department of Intensive Care, Anesthesiology, and Emergency Medicine</p></bio><email xlink:type="simple">immuno2003@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Смолина</surname><given-names>Т. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Smolina</surname><given-names>T. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кандидат медицинских наук, ведущий научный сотрудник лаборатории иммунологии</p></bio><bio xml:lang="en"><p>PhD (Medicine), Leading Research Associate, Laboratory of Immunology</p></bio><email xlink:type="simple">immuno2003@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Тихоокеанский государственный медицинский университет, г. Владивосток<country>Россия</country></aff><aff xml:lang="en">Pacific State Medical University, Vladivostok<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">Научно-исследовательский институт эпидемиологии и микробиологии имени Г.П. Сомова Сибирского отделения Российской академии медицинских наук, г. Владивосток<country>Россия</country></aff><aff xml:lang="en">G.P. Somov Research Institute of Epidemiology and Microbiology, Siberian Branch of Russian Academy of Medical Sciences, Vladivostok<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>30</day><month>06</month><year>2015</year></pub-date><volume>17</volume><issue>3</issue><fpage>221</fpage><lpage>228</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Лазанович В.А., Маркелова Е.В., Смирнов Г.А., Смолина Т.П., 2015</copyright-statement><copyright-year>2015</copyright-year><copyright-holder xml:lang="ru">Лазанович В.А., Маркелова Е.В., Смирнов Г.А., Смолина Т.П.</copyright-holder><copyright-holder xml:lang="en">Lazanovich V.A., Markelova E.V., Smirnov G.A., Smolina T.P.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.mimmun.ru/mimmun/article/view/886">https://www.mimmun.ru/mimmun/article/view/886</self-uri><abstract><p>Экспрессия TLRs на клетках миелоидного ряда имеет ключевое значение в системном реагировании при бактериальном повреждении, активации механизмов врожденного иммунного ответа. В исследование были включены 36 пациентов, исследовали прогностическое значение уровня экспрессии TLR2, TLR4, CD14, HLA-DR на моноцитах у пациентов с сепсисом, в зависимости от тяжести течения и клинических исходов заболевания. В ходе нашего наблюдения не было выявлено достоверных различий экспрессии TLR4 на всех этапах исследования, а также связи экспрессии данного маркера на моноцитах, в зависимости от тяжести течения сепсиса и исходов заболевания. Предикторами неблагоприятного прогноза клинических исходов сепсиса являются низкие показатели MFI на моноцитах TLR2, HLA-DR на 5, 10 сутки и снижение экспрессии CD14 на 10 сутки заболевания. </p></abstract><trans-abstract xml:lang="en"><p>Expression of Toll-like receptors (TLRs) on myeloid cells is of key importance for induction of systemic reactions caused by bacterial damage, and activation mechanisms of innate immune response. The study included thirty-six patients with sepsis in whom we assessed a prognostic value of TLR2, TLR4, CD14, HLA-DR expressed on monocytes, depending on severity of the disease and clinical outcomes. There were neither significant differences in TLR4 expression at all stages of clinical observation, nor correlations between expression of this marker on monocytes and severity of the disease, or outcomes of septic conditions. Low levels of MFI on monocytes TLR2, HLA-DR at 5 and 10 days, like as decreased expression of CD14 on 10th day of the disease were shown to be predictive for poor clinical outcomes of sepsis. </p></trans-abstract><kwd-group xml:lang="ru"><kwd>Toll-рецепторы</kwd><kwd>моноциты</kwd><kwd>сепсис</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Toll-like receptors</kwd><kwd>monocytes</kwd><kwd>sepsis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Киселева Е.П. Новые представления о противоинфекционном иммунитете // Инфекция и иммунитет, 2011. Т. 1, № 1. C. 9-14. [Kisseleva E.P. New aspects of anti-infection immunity]. Infekcii i immunitet = Russian Journal of Infections and Immunity, 2011, Vol. 1, no. 1, рр. 9-14. (In Russ.)]</mixed-citation><mixed-citation xml:lang="en">Киселева Е.П. Новые представления о противоинфекционном иммунитете // Инфекция и иммунитет, 2011. Т. 1, № 1. C. 9-14. [Kisseleva E.P. New aspects of anti-infection immunity]. Infekcii i immunitet = Russian Journal of Infections and Immunity, 2011, Vol. 1, no. 1, рр. 9-14. (In Russ.)]</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Лазанович В.А., Степанюк В.Н., Смирнов Г.А. Маркелова Е.В., Биомаркеры воспаления в прогнозе исхода абдоминального сепсиса // Фундаментальные исследования, 2012. № 4. С. 311-315. [Lazanovich V.A., Stepanyuk V.N., Smirnov G.A., Markelova E.V. Biomarkers inflammation in the forecast of the outcome of the abdominal sepsis]. Fundamental`nye issledovaniya = Fundamental Research, 2012, no. 4, рр. 311-315. (In Russ.)]</mixed-citation><mixed-citation xml:lang="en">Лазанович В.А., Степанюк В.Н., Смирнов Г.А. Маркелова Е.В., Биомаркеры воспаления в прогнозе исхода абдоминального сепсиса // Фундаментальные исследования, 2012. № 4. С. 311-315. [Lazanovich V.A., Stepanyuk V.N., Smirnov G.A., Markelova E.V. Biomarkers inflammation in the forecast of the outcome of the abdominal sepsis]. Fundamental`nye issledovaniya = Fundamental Research, 2012, no. 4, рр. 311-315. (In Russ.)]</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Чикилева И.О., Караулов А.В., Анисимова Н.Ю., Киселевский М.В. Двойственная роль толлподобных рецепторов в регуляции противоопухолевого иммунитета // Иммунология, 2010. № 1. С. 52-55. [Chikileva I.O., Karaulov A.V., Anisimova N.Yu., Kiselevskiy M.V. Dual role TLRs in regulation antitumor immunity]. Immunologiya = Immunology, 2010, no. 1, рр. 52-55. (In Russ.)]</mixed-citation><mixed-citation xml:lang="en">Чикилева И.О., Караулов А.В., Анисимова Н.Ю., Киселевский М.В. Двойственная роль толлподобных рецепторов в регуляции противоопухолевого иммунитета // Иммунология, 2010. № 1. С. 52-55. [Chikileva I.O., Karaulov A.V., Anisimova N.Yu., Kiselevskiy M.V. Dual role TLRs in regulation antitumor immunity]. Immunologiya = Immunology, 2010, no. 1, рр. 52-55. (In Russ.)]</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Armstrong L., Medford A.R., Hunter K.J. Differential expression of Toll-like receptor (TLR)-2 and TLR-4 on monocytes in human sepsis. Clin. Exp. Immunol., 2004, Vol. 136, рр. 312-319.</mixed-citation><mixed-citation xml:lang="en">Armstrong L., Medford A.R., Hunter K.J. Differential expression of Toll-like receptor (TLR)-2 and TLR-4 on monocytes in human sepsis. Clin. Exp. Immunol., 2004, Vol. 136, рр. 312-319.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Brunialti M.K., Martins P.S., Barbosa de Carvalho H. TLR2, TLR4, CD14, CD11B, and CD11C expressions on monocytes surface and cytokine production in patientswith sepsis, severe sepsis, and septic shock. Shock, 2006, Vol. 25, no. 4, рр. 351-357.</mixed-citation><mixed-citation xml:lang="en">Brunialti M.K., Martins P.S., Barbosa de Carvalho H. TLR2, TLR4, CD14, CD11B, and CD11C expressions on monocytes surface and cytokine production in patientswith sepsis, severe sepsis, and septic shock. Shock, 2006, Vol. 25, no. 4, рр. 351-357.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Dessing M.C., Schouten M., Draing C. Role played by Toll-like receptors 2 and 4 in lipoteichoic acidinduced lung inflammation and coagulation. Infect. Dis., 2008, Vol. 197, no. 2, рр. 245-252.</mixed-citation><mixed-citation xml:lang="en">Dessing M.C., Schouten M., Draing C. Role played by Toll-like receptors 2 and 4 in lipoteichoic acidinduced lung inflammation and coagulation. Infect. Dis., 2008, Vol. 197, no. 2, рр. 245-252.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Gaieski D.F., Edwards J.M., Kallan M.J. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit. Care Med., 2013, Vol 41, no. 5, рр. 1167-1174.</mixed-citation><mixed-citation xml:lang="en">Gaieski D.F., Edwards J.M., Kallan M.J. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit. Care Med., 2013, Vol 41, no. 5, рр. 1167-1174.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Hiki N., Berger D., Prigl C. Endotoxin binding and elimination by monocytes: secretionof soluble CD14 represents an inducible mechanism counteracting reduced expression of membrane CD14 in patients with sepsis and in a patient with paroxysmal nocturnal emoglobinuria. Infect. Immun., 1998, Vol. 66, no. 3, pp. 1135-1141.</mixed-citation><mixed-citation xml:lang="en">Hiki N., Berger D., Prigl C. Endotoxin binding and elimination by monocytes: secretionof soluble CD14 represents an inducible mechanism counteracting reduced expression of membrane CD14 in patients with sepsis and in a patient with paroxysmal nocturnal emoglobinuria. Infect. Immun., 1998, Vol. 66, no. 3, pp. 1135-1141.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol., 2010, Vol. 11, no. 5, рр. 373-384.</mixed-citation><mixed-citation xml:lang="en">Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol., 2010, Vol. 11, no. 5, рр. 373-384.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Lukaszewicz A.C., Faivre V., Payen D. Is monocyte HLA-DR expression monitoring a useful tool to predict the risk of secondary infection? Minerva Anestesiol., 2010, Vol. 76 no. 9, рр. 737-743.</mixed-citation><mixed-citation xml:lang="en">Lukaszewicz A.C., Faivre V., Payen D. Is monocyte HLA-DR expression monitoring a useful tool to predict the risk of secondary infection? Minerva Anestesiol., 2010, Vol. 76 no. 9, рр. 737-743.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Moseley P. Stress proteins and the immune response. Immunopharmacology, 2000, Vol. 48, no. 3, рр. 299302.</mixed-citation><mixed-citation xml:lang="en">Moseley P. Stress proteins and the immune response. Immunopharmacology, 2000, Vol. 48, no. 3, рр. 299302.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Opal S.M., Laterre P.F., Francois B. ACCESS Study Group Effect of eritoran, an randomized trial. JAMA, 2013, Vol. 309, рр. 1154-1162.</mixed-citation><mixed-citation xml:lang="en">Opal S.M., Laterre P.F., Francois B. ACCESS Study Group Effect of eritoran, an randomized trial. JAMA, 2013, Vol. 309, рр. 1154-1162.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Gaieski D.F., Edwards J.M., Kallan M.J. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit. Care Med., 2013, Vol. 41, no. 5, рр. 1167-1174.</mixed-citation><mixed-citation xml:lang="en">Gaieski D.F., Edwards J.M., Kallan M.J. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit. Care Med., 2013, Vol. 41, no. 5, рр. 1167-1174.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Ranieri V.M., Thompson B.T., Barie P.S. Drotrecogin alfa (activated) in adults with septic shock. PROWESSSHOCK Study Group. N. Engl. J. Med, 2012, Vol. 366, no. 22, рр. 2055-2064.</mixed-citation><mixed-citation xml:lang="en">Ranieri V.M., Thompson B.T., Barie P.S. Drotrecogin alfa (activated) in adults with septic shock. PROWESSSHOCK Study Group. N. Engl. J. Med, 2012, Vol. 366, no. 22, рр. 2055-2064.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Schaaf B., Luitjens K., Goldmann T., van Bremen T., Sayk F., Dodt C., Dalhoff K., Droemann D. Mortality in human sepsis is associated with downregulation of Toll -like receptor 2 and CD14 expression on blood monocytes. Diagn. Pathol., 2009, no. 16, рр. 4-12.</mixed-citation><mixed-citation xml:lang="en">Schaaf B., Luitjens K., Goldmann T., van Bremen T., Sayk F., Dodt C., Dalhoff K., Droemann D. Mortality in human sepsis is associated with downregulation of Toll -like receptor 2 and CD14 expression on blood monocytes. Diagn. Pathol., 2009, no. 16, рр. 4-12.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Tsung A., Sahai R., Tanaka H.The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J. Exp. Med., 2005, Vol. 201, no. 7, рр. 1135-1143.</mixed-citation><mixed-citation xml:lang="en">Tsung A., Sahai R., Tanaka H.The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J. Exp. Med., 2005, Vol. 201, no. 7, рр. 1135-1143.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Wittebole X., Castanares-Zapatero D., Laterre P.F. Toll-like receptor 4 modulation as a strategy to treat sepsis. Mediators Inflamm., 2010, Vol. 2010, рр. 5683-5696.</mixed-citation><mixed-citation xml:lang="en">Wittebole X., Castanares-Zapatero D., Laterre P.F. Toll-like receptor 4 modulation as a strategy to treat sepsis. Mediators Inflamm., 2010, Vol. 2010, рр. 5683-5696.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Xu J., Zhang X., Pelayo R. Extracellular histones are major mediators of death in sepsis. Nat. Med., 2009, Vol. 15, no. 11, рр.1318-1321.</mixed-citation><mixed-citation xml:lang="en">Xu J., Zhang X., Pelayo R. Extracellular histones are major mediators of death in sepsis. Nat. Med., 2009, Vol. 15, no. 11, рр.1318-1321.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
